0001630176 --12-31 false 2026 Q1 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0001630176 2026-01-01 2026-03-31 0001630176 2026-03-31 0001630176 2026-05-14 0001630176 2026-03-31 2026-03-31 0001630176 2025-12-31 2025-12-31 0001630176 2025-12-31 0001630176 2025-01-01 2025-03-31 0001630176 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001630176 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001630176 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001630176 2024-12-31 0001630176 us-gaap:CommonStockMember 2024-12-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001630176 us-gaap:TreasuryStockCommonMember 2024-12-31 0001630176 us-gaap:RetainedEarningsMember 2024-12-31 0001630176 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001630176 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001630176 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001630176 2025-03-31 0001630176 us-gaap:CommonStockMember 2025-03-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001630176 us-gaap:TreasuryStockCommonMember 2025-03-31 0001630176 us-gaap:RetainedEarningsMember 2025-03-31 0001630176 us-gaap:CommonStockMember 2026-03-31 0001630176 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001630176 us-gaap:TreasuryStockCommonMember 2026-03-31 0001630176 us-gaap:RetainedEarningsMember 2026-03-31 0001630176 2024-03-31 0001630176 us-gaap:PatentsMember 2026-03-31 0001630176 us-gaap:PatentsMember 2025-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001630176 2025-01-01 2025-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001630176 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001630176 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001630176 2014-12-19 2026-03-31 0001630176 fil:RelatedParty1Member 2026-01-01 2026-03-31 0001630176 fil:UnsecuredDebtAMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtAMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:UnsecuredDebtIMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtIMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:UnsecuredDebtLMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtLMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:UnsecuredDebtNMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtNMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:UnsecuredDebtOMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtOMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:UnsecuredDebtPMemberfil:RelatedParty1Member 2026-03-31 0001630176 fil:UnsecuredDebtPMemberfil:RelatedParty1Member 2025-12-31 0001630176 fil:RelatedParty1Member 2026-03-31 0001630176 fil:RelatedParty1Member 2025-12-31 0001630176 fil:HendersonNvMember 2026-03-31 0001630176 fil:SarasotaFlMember 2026-03-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2026-01-01 2026-03-31 0001630176 fil:UnsecuredDebtDMemberus-gaap:NotesPayableOtherPayablesMember 2026-03-31 0001630176 fil:UnsecuredDebtDMemberus-gaap:NotesPayableOtherPayablesMember 2025-12-31 0001630176 fil:SecuredDebtEMemberus-gaap:NotesPayableOtherPayablesMember 2026-03-31 0001630176 fil:SecuredDebtEMemberus-gaap:NotesPayableOtherPayablesMember 2025-12-31 0001630176 fil:SecuredDebtFMemberus-gaap:NotesPayableOtherPayablesMember 2026-03-31 0001630176 fil:SecuredDebtFMemberus-gaap:NotesPayableOtherPayablesMember 2025-12-31 0001630176 fil:SecuredDebtGMember 2026-03-31 0001630176 fil:SecuredDebtGMember 2025-12-31 0001630176 fil:UnsecuredDebtJMember 2026-03-31 0001630176 fil:UnsecuredDebtJMember 2025-12-31 0001630176 fil:SecuredDebtKMember 2026-03-31 0001630176 fil:SecuredDebtKMember 2025-12-31 0001630176 fil:SecuredDebtMMember 2026-03-31 0001630176 fil:SecuredDebtMMember 2025-12-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2026-03-31 0001630176 us-gaap:NotesPayableOtherPayablesMember 2025-12-31 0001630176 us-gaap:ConvertibleDebtMember 2026-01-01 2026-03-31 0001630176 fil:ConvertiblePromissoryNote1Memberus-gaap:ConvertibleDebtMember 2026-03-31 0001630176 fil:ConvertiblePromissoryNote1Memberus-gaap:ConvertibleDebtMember 2025-12-31 0001630176 fil:ConvertiblePromissoryNote2Memberus-gaap:ConvertibleDebtMember 2026-03-31 0001630176 fil:ConvertiblePromissoryNote2Memberus-gaap:ConvertibleDebtMember 2025-12-31 0001630176 fil:ConvertiblePromissoryNote3Memberus-gaap:ConvertibleDebtMember 2026-03-31 0001630176 fil:ConvertiblePromissoryNote3Memberus-gaap:ConvertibleDebtMember 2025-12-31 0001630176 fil:ConvertiblePromissoryNote4Memberus-gaap:ConvertibleDebtMember 2026-03-31 0001630176 fil:ConvertiblePromissoryNote4Memberus-gaap:ConvertibleDebtMember 2025-12-31 0001630176 us-gaap:ConvertibleDebtMember 2026-03-31 0001630176 us-gaap:ConvertibleDebtMember 2025-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-01-01 2026-03-31 0001630176 fil:UponIssuanceMember 2026-01-01 2026-03-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-01-01 2024-12-31 0001630176 fil:UponIssuanceMember 2024-01-01 2024-12-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2026-03-31 0001630176 fil:UponIssuanceMember 2026-03-31 0001630176 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-12-31 0001630176 srt:MinimumMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-12-31 0001630176 srt:MaximumMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-12-31 0001630176 fil:UponIssuanceMember 2024-12-31 0001630176 2017-02-28 0001630176 us-gaap:SeriesAPreferredStockMember 2017-02-28 0001630176 2018-01-31 0001630176 2018-04-30 0001630176 us-gaap:SeriesAPreferredStockMember 2017-10-16 0001630176 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001630176 2023-01-01 2023-03-31 0001630176 us-gaap:CommonStockMember 2022-02-02 2022-02-02 0001630176 fil:WarrantsMember 2026-01-01 2026-03-31 0001630176 fil:WarrantsMember 2025-12-31 0001630176 fil:WarrantsMember 2025-12-31 2025-12-31 0001630176 fil:WarrantsMember 2026-03-31 2026-03-31 0001630176 fil:WarrantsMember 2026-03-31 0001630176 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2026-01-01 2026-03-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2025-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2025-12-31 2025-12-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2026-03-31 2026-03-31 0001630176 fil:OmnibusStockGrantAndOptionPlanMember 2026-03-31 0001630176 fil:RestrictedStockUnitsMember 2025-12-31 0001630176 fil:RestrictedStockUnitsMember 2026-01-01 2026-03-31 0001630176 fil:RestrictedStockUnitsMember 2026-03-31 0001630176 fil:ShareOptionsUnitsAndWarrantsMember 2026-01-01 2026-03-31 0001630176 fil:March312024Member 2026-01-01 2026-03-31 0001630176 fil:ConsolidatedMember 2026-01-01 2026-03-31 0001630176 fil:BergametMember 2026-01-01 2026-03-31 0001630176 fil:GummyUsaMember 2026-01-01 2026-03-31 0001630176 fil:UbnMember 2026-01-01 2026-03-31 0001630176 us-gaap:CorporateMember 2026-01-01 2026-03-31 0001630176 fil:ConsolidatedMember 2026-03-31 0001630176 fil:BergametMember 2026-03-31 0001630176 fil:GummyUsaMember 2026-03-31 0001630176 fil:UbnMember 2026-03-31 0001630176 us-gaap:CorporateMember 2026-03-31 0001630176 fil:March312023Member 2026-01-01 2026-03-31 0001630176 fil:ConsolidatedMember 2025-01-01 2025-03-31 0001630176 fil:BergametMember 2025-01-01 2025-03-31 0001630176 fil:GummyUsaMember 2025-01-01 2025-03-31 0001630176 fil:UbnMember 2025-01-01 2025-03-31 0001630176 us-gaap:CorporateMember 2025-01-01 2025-03-31 0001630176 fil:ConsolidatedMember 2025-03-31 0001630176 fil:BergametMember 2025-03-31 0001630176 fil:GummyUsaMember 2025-03-31 0001630176 fil:UbnMember 2025-03-31 0001630176 us-gaap:CorporateMember 2025-03-31

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________.

Commission file number 000-55572

Healthy Extracts Inc.

(Exact name of registrant as specified in its charter)

Nevada	47-2594704
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

7375 Commercial Way, Suite 125	89011
Henderson, NV	(Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code (702) 463-1004

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

None

N/A

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of May 14, 2026, there were 16,890,868 shares of common stock, $0.001 par value, issued and outstanding.

HEALTHY EXTRACTS INC.

FORM 10-Q QUARTERLY REPORT

FOR THE THREE MONTHS ENDED MARCH 31, 2026

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosure About Market Risks	7
Item 4.	Controls and Procedures	7

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	8
Item 1A.	Risk Factors	8
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	8
Item 3.	Defaults Upon Senior Securities	8
Item 4.	Mine Safety Disclosures	8
Item 5.	Other Information	8
Item 6.	Exhibits	9

SIGNATURES		10

PART I – FINANCIAL INFORMATION

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider” or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

ITEM 1Financial Statements

HEALTHY EXTRACTS INC.

CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2026 AND DECEMBER 31, 2025

(UNAUDITED)

	MARCH 31,	DECEMBER 31,
	2026	2025
ASSETS

CURRENT ASSETS
Cash	$164,385	$146,935
Accounts receivable	253,668	187,750
Inventory, net	520,752	843,357
Offering costs	149,274	149,274
Total current assets	1,088,079	1,327,317

Fixed assets	4,076,915	4,233,083
Deposit	34,201	99,767
Goodwill	21,123,922	21,123,922
Patents/Trademarks	526,647	526,647
Right of use asset, net - non-current	469,074	513,929
Total other assets	26,230,759	26,497,347

TOTAL ASSETS	27,318,838	27,824,664


LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES
Accounts payable	149,179	108,496
Accrued interest payable	5,253	5,118
Accrued interest payable - related party	96,257	76,401
Accrued liabilities	459,466	613,645
Lease liabilities - current	191,150	171,930
Notes payable - related party - current	683,711	601,250
Convertible debt, net of discount - current	-	111,330
Total current liabilities	1,585,015	1,688,169

Lease liabilities - long-term	280,403	344,265
Notes payable	1,257,927	1,246,670
Notes payable - related party - non-current	137,752	156,835
Convertible debt, net of discount - non-current	6,750	6,750
Derivative liabilities	69,392	352,411
Total non-current liabilities	1,752,223	2,106,930

Total current and total liabilities	3,337,239	3,795,099


STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively	-	-
Common stock, $0.001 par value, 50,000,000 shares authorized, 16,890,868 shares issued and outstanding as of March 31, 2026, and 16,870,868 shares issued and outstanding as of December 31, 2025	368,433	368,413
Additional paid-in capital	43,940,618	43,788,013
Treasury stock, at cost, 4,166 shares, respectively	(5,400)	(5,400)
Accumulated deficit	(20,322,053)	(20,121,462)
Total stockholders' equity	23,981,599	24,029,564

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$27,318,838	$27,824,664

The accompanying notes are an integral part of these unaudited consolidated financial statements.

F-1

HEALTHY EXTRACTS INC.

CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE THREE MONTHS ENDING MARCH 31, 2026 AND 2025

(UNAUDITED)

	FOR THE THREE MONTHS ENDINGMARCH 31,
	2026	2025

REVENUE
Revenue	$1,610,744	$931,280
Net revenue	1,610,744	931,280

COST OF REVENUE
Cost of goods sold	622,043	506,295
Total cost of revenue	622,043	506,295

GROSS PROFIT	988,701	424,985

OPERATING EXPENSES
General and administrative	1,317,403	533,833
Total operating expenses	1,317,403	533,833

OTHER INCOME (EXPENSE)
Interest expense, net of interest income	(84,907)	(34,558)
Change in fair value on derivative	283,019	(255,454)
Gain/loss of disposal of assets	(70,000)	-

Total other income (expense)	128,112	(290,011)

Net income/(loss) before income tax provision	(200,590)	(398,860)

NET INCOME/(LOSS)	$(200,590)	$(398,860)

Income/(Loss) per share - basic and diluted	$(0.01)	$(0.13)

Weighted average number of shares outstanding - basic and diluted	16,884,868	2,989,406

The accompanying notes are an integral part of these unaudited consolidated financial statements.

F-2

HEALTHY EXTRACTS INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDING MARCH 31, 2026 AND 2025

(UNAUDITED)

			Additional
	Common Stock		Paid-In	Treasury	Accumulated
	Shares	Amount	Capital	Stock	Deficit	Total

Balance - March 31, 2024	2,963,906	354,502	19,058,074	-	(19,260,931)	151,646

Fair value of options and warrants issued	-	-	48,991	-	-	48,991

Net (loss) for the period	-	-	-	-	(398,860)	(398,860)

Balance - March 31, 2025	2,989,406	354,532	19,350,579	(5,400)	(19,639,203)	60,508

Issuance of common stock for services	20,000	20	38,804	-	-	38,824

Fair value of options and warrants issued	-	-	113,801	-	-	113,801

Net (loss) for the period	-	-	-	-	(200,590)	(200,590)

Balance - March 31, 2026	16,890,868	368,433	43,940,618	(5,400)	(20,322,053)	23,981,599

The accompanying notes are an integral part of these unaudited consolidated financial statements.

F-3

HEALTHY EXTRACTS INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE THREE MONTHS ENDING MARCH 31, 2026 AND 2025

(UNAUDITED)

	FOR THE THREE MONTHS ENDING MARCH 31,
	2026	2025
Cash Flows from Operating Activities:
Net Income/(Loss)	$(200,590)	$(398,860)

Adjustments to reconcile net loss to net cash
Used in operating activities:
Depreciation and amortization	156,168	204
Common stock issued for services	38,824	-
Gain/loss of disposal of assets	70,000	-
Interest expense	84,907	34,558
Warrants issued for services	113,801	48,991
Change in fair value on derivative liability	(283,019)	255,454
Changes in operating assets and liabilities:
Accounts receivable	(65,918)	(58,977)
Deposit	(4,434)	-
Inventory	322,605	218,589
Accounts payable	40,683	28,672
Accrued liabilities	(157,396)	(75,885)
Accrued interest payable	(75,210)	6,337
Accrued interest payable - related party	69,781	1,588
Lease liability - current	(4,233)	59,544
Lease liability - long-term	-	(60,194)
Net Cash provided by Operating Activities	105,970	60,021

Cash Flows from Investing Activities:
Cash flows provided by (used in) Investing Activities:	-	-

Cash Flows from Financing Activities:

Payments for repayment of convertible debt	(106,000)	(37,212)
Proceeds from issuance of noted payable	176,000	-
Payments for repayment of notes payable	(110,492)	(2,629)
Payments for repayment of noted payable - related party	(21,580)	(13,402)
Interest payment of notes payable	(25,239)	-
Interest payment of notes payable - related party	(1,209)	-
Net Cash used in Financing Activities	(88,520)	(53,243)

Increase in cash	17,450	6,778
Cash at beginning of period	146,935	112,020
Cash at end of period	$164,385	$118,798

The accompanying notes are an integral part of these unaudited consolidated financial statements.

F-4

HEALTHY EXTRACTS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2026 and 2025

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Healthy Extracts Inc. (the “Company”) was incorporated in the State of Nevada on December 19, 2014 as Grey Cloak Tech Inc. On October 23, 2020, the Company changed its name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect its business. The Company has acquired BergaMet NA, LLC and Ultimate Brain Nutrients, LLC which market and sell health supplemental products. On October 1, 2025, the Company acquired Gummy USA which manufactures supplemental gummies.

On July 19, 2025, the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Gummy USA LLC (“GUSA”) and its sole-member, Donald Swanson (“Swanson”), pursuant to which the Company acquired one-hundred percent (100%) of the outstanding membership interests of GUSA, which became its wholly-owned subsidiary. As consideration for the purchase, the Company issued thirteen million seventy-five thousand nine hundred twenty (13,075,920) shares of its common stock (the “Purchase Shares”) which represented 77.5% of its issued and outstanding common stock after the transaction, to Swanson. In addition, Swanson was granted anti-dilution rights to maintain that same ownership percentage in the event of the exercise of any of the Company’s 154,306 outstanding options and warrants.

On September 26, 2025, the Company rescinded the MIPA as of its effective date. On September 30, 2025, effective as of October 1, 2025, the Company entered into an Agreement and Plan of Merger with GUSA and Swanson, pursuant to which GUSA was merged with and into the Company’s wholly-owned subsidiary, HE Gummy USA, Inc., a Nevada corporation. The Company re-issued the Purchase Shares, which continued to represent 77.5% of its issued and outstanding common stock after the transaction, to Swanson. In addition, Swanson was granted anti-dilution rights to maintain that same ownership percentage in the event of the exercise of any of the Company’s 154,306 outstanding options and warrants.

In connection with the transaction, as of September 30, 2025 and as consideration for the purchase, the Company issued thirteen million seventy-five thousand nine hundred twenty (13,075,920) shares of its common stock (the “Purchase Shares”) which represented 77.5% of its issued and outstanding common stock after the transaction, to Donald Swanson. In addition, Swanson was granted anti-dilution rights to maintain that same ownership percentage in the event of the exercise of any of the Company’s 154,306 outstanding options and warrants.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying audited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of December 31, 2025 and the results of operations and cash flows for the periods presented. The results of operations for the year ended December 31, 2025 are not necessarily indicative of the operating results for the full fiscal year or any future period. These audited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s form 10-K for the year ended December 31, 2025 filed with the SEC on April 8, 2026.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

F-5

In regards to inventory write-offs and allowances, the Company determines the net realizable value by using the various factors as follows: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory. Management has provided for any risks in the current inventory allowance booked.

As for revenue adjustments for discounts, allowances and refunds, the Company treats each of these items differently. When it comes to revenue discounts, the Company will create the invoice for the product sold which will include any discounts given. These discounts usually happen for a short period of time for sales that the Company will offer around holidays. Due to the revenue being recognized once the order has shipped, less any applicable discount, the Company books this transaction at the net order transaction amount. In regards to allowances and refunds for revenue adjustments, due to the fact that its refund percentage is less than 1% the Company decided the need for an estimated adjustment for allowances and refunds was not material. If the Company does receive any returned orders, it will directly book those orders as refunds the day it receives the call from the customer requesting the refund. The Company will book the credit memo at the full value of the customer original order.

For purposes of clarity and ease of presentation, all dollar amounts in these financial statements have been rounded to the nearest whole number. However, the underlying data used in the calculations is not rounded, and the totals presented may differ by a small amount due to rounding. These differences are considered immaterial and do not affect the overall financial position or results of operations.

Cash

Cash includes cash in banks, money market funds, and certificates of term deposits with maturities of less than three months from inception, which are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss in value.

Accounts Receivables

Accounts receivables are recorded at the invoice amount and do not bear interest.

Inventory

Inventories consist of health supplements held for sale in the ordinary course of business. The Company uses the weighted average cost method to value its inventories at the lower of cost and net realizable value. In pursuant to ASC 330-10-50-6, the components of inventory cost include raw materials, labor, and overhead. Additionally, the weighted average cost per unit is used as a basis to determine the cost amounts removed from inventory as the aggregate number of units expected to be delivered under each order. Finally, the net realizable value is determined by using the various factors as following: excess or slow-moving inventories (12 months or more of inventory on hand), expiration dates (within 12 months of the current reporting period), current and future product demand, production planning, and market conditions. If any of these factors are found in the reporting period, management will review each item and determine if any additional allowances or write-offs need to be made. A change in any of these variable’s factors could result in an adjustment to inventory.

An allowance for inventory was established in 2018 and is evaluated each quarter to determine if all items are still sellable due to the factors listed above. As of March 31, 2026 and December 31, 2025, the total of inventory allowance was $88,476 and $90,091. The following are the classes held in inventory as of March 31, 2026 and December 31, 2025:

F-6

	DECEMBER 31,	DECEMBER 31,
	2025	2025
Inventory

Inventory Classes:
Raw Materials	$243,096	$534,514
Finished Goods	364,813	369,345
Work in process	1,319	29,589
Total inventory	609,228	933,448
Inventory allowance	(88,476)	(90,091)
Total inventory, net	520,752	843,357

Property and Equipment

The Company’s property and equipment are recorded at cost and depreciated using the straight-line method over the useful lives of the assets, generally from three to seven years. Upon sale or disposal of property and equipment, the related asset cost and accumulated depreciation or amortization are removed from the respective accounts and any gain or loss is reflected in current operations.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets established in connection with business combinations consist of patents, trademarks, and trade names. The impairment test for identifiable indefinite-lived intangible assets consists of a comparison of the estimated fair value of the intangible asset with it carrying value. If the carrying value exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. With the acquisition of Ultimate Brain Nutrients on April 3, 2020 the Company added a purchasing value of $315,604 in patents to its balance sheet.

As of March 31, 2026, the Company believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.

Goodwill

In accordance with Goodwill and Other Intangible Assets, goodwill is defined as the excess of the purchase price over the fair value assigned to individual assets acquired and liabilities assumed and is tested for impairment at the reporting unit level on an annual basis in the Company's fourth fiscal quarter or more frequently if indicators of impairment exist. The performance of the test involves a two-step process. The first step of the impairment test involves comparing the fair value of the Company's reporting units with each respective reporting unit's carrying amount, including goodwill. The fair value of reporting units is generally determined using the income approach. If the carrying amount of a reporting unit exceeds the reporting unit's fair value, the second step of the goodwill impairment test is performed to determine the amount of any impairment loss. The second step of the goodwill impairment test involves comparing the implied fair value of the reporting unit's goodwill with the carrying amount of that goodwill. No goodwill impairment indicators were present, for the goodwill listed on the books as of March 31, 2026, after working through its analysis of goodwill during the year ended March 31, 2026.

The Company has determined that the method applied represents the fair value of the asset group principally because the valuation of the intangibles with the asset group is based on the anticipated cash flows related to the revenue stream from its customers. The asset group excludes goodwill, long term non-operational assets and liabilities and cash. As such, the principal value from the asset group relates to the cash inflows from its customers and the cash outflows required to service these customers. The fair value for the asset group consists of the following:

·Fair value of net revenues: computed using the income approach. The key input to these computations is the anticipated cash inflows from customers. These valuations include 100% of the cash inflows related to the customer base, and taking cash outflows into consideration.

F-7

·Fair value of working capital (including accounts receivable, inventory, accrued expenses, and accounts payables). Due to the short-term nature of the working capital, book value has been determined to be fair value. These accounts represent either avoided future outflows (inventory, prepaids) or future cash flows (accrued expense, AP and AR) related to customer sales.

·Fair value of five years of revenue (2025 to 2029): the Company discounted its cash flows to the anticipated cash projected to be received. The Company also projected the anticipated cash outflows required to service these customers. If the asset group was to be valued as a whole, the Company would expect an income approach based on the revenues being generated from the customers and expenses required to service those customers, appropriately adjusted for the working capital position. The sum of these values reasonably approximates this approach.

The Company’s revenue streams align directly with the intangibles, which were recorded as a result of the BergaMet acquisition in fiscal 2019 and the merger of Gummy USA LLC on October 1, 2025. For purposes of the Step 2 recoverability test under ASC 360 subsection 2.3., the net revenues from BergaMet and Gummy USA LLC customers base were used. The revenue stream fairly reflects anticipated future cash flows; accordingly, the intangibles associated with these revenue streams have been tested with the expected cash flows.

Long-term investment

On July 19, 2025, the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Gummy USA LLC (“GUSA”) and its sole member, Donald Swanson (“Swanson”). Under the terms of the MIPA, the Company acquired 100% of the outstanding membership interests of GUSA, and GUSA became a wholly owned subsidiary of the Company. As consideration for the acquisition, the Company issued 13,075,920 shares of its common stock (the “Purchase Shares”) to Swanson. The Purchase Shares represented approximately 77.5% of the Company’s issued and outstanding common stock immediately following the transaction. The total fair value of the shares issued was $23,536,656.

During July 2025, the Company identified certain unforeseen complications related to the structure and timing of the transaction and determined that it would pursue a rescission of the MIPA, while continuing to work toward completing a revised merger with GUSA. On September 26, 2025, the Company formally rescinded the MIPA, effective as of its original date.

On September 30, 2025, effective as of October 1, 2025, the Company entered into an Agreement and Plan of Merger with GUSA and Swanson, pursuant to which GUSA was merged with and into the Company’s wholly owned subsidiary, HE Gummy USA, Inc., a Nevada corporation.

Management did not cancel or reverse the previously issued Purchase Shares upon rescission of the MIPA. Instead, the related amount has been recorded and presented as a long-term investment as of March 31, 2026, pending completion of the merger and related consolidation analysis.

Debt with Warrants

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations using the straight-line method. The offset to the contra-liability is recorded as either equity or liability in the Company’s consolidated balance sheets depending on the accounting treatment of the warrants. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

Convertible Debt – Derivative Treatment

When the Company issues debt with a conversion feature, it must first assess whether the conversion feature meets the requirements to be treated as a derivative, as follows: (a) one or more underlying’s, typically the price of its common stock; (b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; (c) no initial net investment, which typically excludes the amount

F-8

borrowed; and (d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both (a) indexed to its own stock; and (b) classified in stockholders’ equity in its balance sheet.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, the Company estimates the fair value of the convertible debt derivative using a Black-Scholes Option-Pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. The derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the statement of operations. The debt discount is amortized through interest expense over the life of the debt using the straight-line method.

Revenue Recognition

The Company applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) topic 606, Revenue from Contracts with Customers (ASC 606). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes all of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 requires us to identify distinct performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. When distinct performance obligations exist, the Company allocates the contract transaction price to each distinct performance obligation. The standalone selling price is used to allocate the transaction price to the separate performance obligations. The Company recognizes revenue when, or as, the performance obligation is satisfied.

Mostly, revenues are recognized at the time of shipment to the customer with the price being fixed and determinable and collectability assured, provided title and risk of loss is transferred to the customer. Most of the Company’s shipping and handling costs are built into the transaction price, but if the customer asks for express shipping, the costs charged to customers are classified as sales, and the shipping and handling costs incurred are included in cost of sales.

The Company’s subsidiary, BergaMet N.A., LLC, recognizes revenue from its main source – e-commerce revenue. Its sales channels include the Company’s subsidiary website channel or any other selling channel like Amazon, doctors’ offices, and walk-in sales. All of its customer sales for Healthy Extracts Inc. and Ultimate Brain Nutrients, LLC are recognized as revenue under the subsidiary of BergaMet N.A., LLC. All three divisions of the Company sell plant-based nutraceuticals to its end using customers. Gummy USA, LLC recognizes revenue from one main source – manufacturing. The Company’s sales channels are through third party customers by white labeling the products produced.

The Company evaluates the criteria pursuant to ASC 606-10-55. Some of the different considerations that it uses because of their significance are as follows: Collectability - payment has to be made prior to shipment unless the customer has agreed upon terms. Guaranties – the Company offers a money back guarantee to customers if they are unhappy with its products. Principal versus Agent Considerations - currently the Company is the principal and has not engaged an agent at this time and has not recognized any revenues under the agent considerations.

Revenue is recognized when, or as, control of a promised merchandise or service is shipped to the customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring title of those products or services and are recorded net of and discounts or allowances. Shipping costs paid by the customer are included in revenue. Merchandise sales are fulfilled with inventory held in the Company’s warehouses in Henderson, NV and Sarasota, FL. Therefore, the Company’s contracts have a single performance obligation (shipment of product).

F-9

If the Company receives a request for refund on a customer obligation, the Company will refund the full cost of the obligation due to its money back guarantee. Historically, the Company has done a valuation of its sales allowance account (customer returns). In 2025, the Company’s return percentage was 0.007% of sales and 2024 was 0.007% of sales. Due to the low refund percentage management decided there was not a need for an estimated adjustment for allowances and refunds due to materiality.

Revenue recognition is evaluated through the following five-step process:

1.identification of the contract with a customer;

2.identification of the performance obligations in the contract;

3.determination of the transaction price;

4.allocation of the transaction price to the performance obligations in the contract; and

5.recognition of revenue when or as a performance obligation is satisfied.

These steps are met when an order is received, a price agreed and the product shipped or delivered to that customer.

Concentration

There is no concentration of revenue for the year ended December 31, 2025 and for the months ended March 31, 2026 for BergaMet N.A., LLC because the revenue was earned from multiple customers, but Gummy USA LLC does have a concentration of revenue for the months ended March 31, 2026 due to only having two customers.

Income Taxes

The Company uses the liability method of accounting for income taxes under which deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the accounting bases and the tax bases of the Company’s assets and liabilities. The deferred tax assets and liabilities are computed using enacted tax rates in effect for the year in which the temporary differences are expected to reverse.

The Company's deferred income taxes include certain future tax benefits. The Company records a valuation allowance against any portion of those deferred income tax assets when it believes, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred income tax asset will not be realized.

The Company has adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the consolidated financial statements and applies to all income tax positions. Each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the consolidated financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At March 31, 2026 and December 31, 2025, there were no uncertain tax positions that required accrual.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

F-10

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The derivative liability in connection with the conversion feature of the convertible debt, classified as a Level 3 liability, is the only financial liability measure at fair value on a recurring basis. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations.

The Company measures and reports certain financial instruments as liabilities at fair value on a recurring basis. The fair value of these instruments as of March 31, 2026 and December 31, 2025 was as follows:

	Fair Value	Level 1	Level 2	Level 3
Fair Value at December 31, 2024	$625,420	-	-	$625,420
Derivative liability	(273,009)	-	-	(273,009)
Fair Value at December 31, 2025	$352,411	-	-	$352,411
Derivative liability	(283,019)	-	-	(283,019)
Fair Value at March 31, 2026	$69,392	-	-	$69,392

March 31, 2026

		Level 1		Level 2		Level 3		Total
Derivative liability		-		-		69,392		$69,392

December 31, 2025

		Level 1		Level 2		Level 3		Total
Derivative liability		-		-		352,411		$352,411

The details of derivative liability transactions for the months ended March 31, 2026 and the year ended December 31, 2025 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2024		$625,420
Issued during the year ended December 31, 2025		-
Derivative liabilities debt discount		-
Change in fair value recognized in operations		(184,907)
Converted during the year ended December 31, 2025		(88,102)
Balance, December 31, 2025		$352,411
Issued during the month ended March 31, 2026		-
Derivative liabilities debt discount		-
Change in fair value recognized in operations		(261,734)
Converted during the month ended March 31, 2026		(21,285)
Balance, March 31, 2026		$69,392

The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the months ended March 31, 2026 and year ended December 31, 2025.

F-11

The Company determines the fair value of the derivative liability based on Level 3 inputs using the Black-Scholes option pricing model. The significant unobservable input assumptions that can significantly change the fair value includes common share price; amount of principal and accrued interest convertible into shares as of the conversion date, and the number of shares issuable upon conversion; expected exercise price; expected term; volatility; and risk-free interest rate.

Convertible Instruments

Convertible debt – derivative treatment

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

If the conversion feature within convertible debt meets the requirements to be treated as a derivative, the Company estimates the fair value of the convertible debt derivative using the Black-Sholes option pricing model upon the date of issuance. If the fair value of the convertible debt derivative is higher than the face value of the convertible debt, the excess is immediately recognized as interest expense. Otherwise, the fair value of the convertible debt derivative is recorded as a liability with an offsetting amount recorded as a debt discount, which offsets the carrying amount of the debt. If the convertible debt is viewed as short-term, management chooses to expense the full debt discount in the period incurred is recorded as a gain or loss in the consolidated statement of operations. The convertible debt derivative is revalued at the end of each reporting period and any change in fair value is recorded as a gain or loss in the consolidated statement of operations.

Convertible debt – beneficial conversion feature

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, any discounts, if applicable, to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts, if applicable, under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Debt modifications and extinguishments

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded under change in fair value on derivative, in the consolidated operation statements, as a gain or loss on extinguishment of the two separate liabilities. During the month ended March 31, 2026, the Company did not issue any convertible debt.

F-12

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements of five–step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract cost, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting period beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.

The Company’s revenues are recognized when control of the promised goods or services is transferred to its clients (upon shipment of goods) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods and services. To achieve this core principle, the Company applies the following five steps: (1) Identify the contract with a client; (2) Identify the performance obligations in the contract; (3) Determine the transaction price; (4) Allocate the transaction price to performance obligations in the contract; and (5) Recognize revenues when or as the Company satisfies a performance obligation.

The Company adopted ASC 2014-09 on January 1, 2019. Although the new revenue standard is expected to have an immaterial impact, if any, on its ongoing net income, the Company did implement changes to its processes related to revenue recognition and the control activities with them.

The Company leases its office and warehouse space under non-cancellable capital leases. The Company accounts for this lease in accordance with ASC 842. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Since its lease arrangements do not provide an implicit rate, the Company uses its estimated incremental borrowing rate for the expected remaining lease term at commencement date in determining the present value of future lease payments.

The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Capital lease expense is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease payments to measure the lease liability and are expensed as incurred.

Finance lease expense is comprised of both interest expense, which is recognized using the effective interest method, and amortization of the right-of-use assets. These expenses are presented consistently with the presentation of other interest expense and amortization or depreciation of similar assets.

Common area maintenance fees (or CAMs) and other charges related to leases are expensed as incurred. See Note 5 — Right-of-Use Assets and Lease Liabilities for further discussion of the Company’s lease activities.

Common Stock Purchase Warrants

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity's Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside its control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification is required.

F-13

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated revenues from operations which has stabilized its cash flow from be negative to neutral over the past year. Since its inception, the Company has been engaged substantially in financing activities and developing its business plan and expenses. As a result, the Company incurred accumulated net losses from Inception (December 19, 2014) through the month ended March 31, 2026 of $20,322,053. Due to its neutral cash flow, the Company has doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, most of the Company’s development activities since inception have been financially sustained through equity financing but it is using all additional cash flow to help support the Company’s growth and research and development of new products. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity’s ability to continue as a going concern.

NOTE 4 – RELATED PARTY

For the month ended March 31, 2026 and the year ended December 31, 2025, the Company had expenses totaling $0 and $0 respectively, to an officer and director for salaries, which is included in general and administrative expenses on the accompanying consolidated statement of operations.

Note	Issuance Date	Maturity Date	Interest Rate	Original Principal Amount	Balance at March 31, 2026	Balance at December 31, 2025
Unsecured debt A	March 2019, March and June 2020	No due date	0%	$ 866	$ 666	$ 666
Unsecured debt I	January 1, 2024	June 1, 2025	15%	$ 84,965	$ 177,500	$ 177,500
Unsecured debt L	November 14, 2024	November 13, 2027	15%	$220,000	$ 137,086	$ 156,169
Unsecured debt N	July 21, 2025	July 20, 2026	12%	$325,000	$ 349,375	$ 341,250
Unsecured debt O	July 31, 2025	January 31, 2026	12%	$75,000	$ 82,500	$ 82,500

Unsecured debt P	December 13, 2025	December 12, 2026	7.49%	$75,000	$ 74,336	$ 75,000

Total notes payable				$863,331	$ 821,463	$ 758,085
Debt discount and deferred financing costs				-	-	-
Total notes payable, net				$863,331	$ 821,463	$ 758,085

Unsecured debt A: On March 2, 2020, the Company received an unsecured loan of $200 from a shareholder. Additionally, during in March and June 2019, the Company received an additional loan of $666 from another shareholder. Both of these notes are unsecured and do not have a payment due date at an interest rate of 0.00%. During the fourth quarter 2024, the Company made a payment of $200 towards part of this unsecured loan. As of March 31, 2026, the outstanding principal balance of unsecured debt A totaled $666.

Unsecured debt I: On January 1, 2024, the Company agreed and signed a new unsecured line of credit in the principal of up to $180,000. The net proceeds from this line of credit were $82,000. The loan is unsecured and was due for repayment on June 30, 2025. Interest will accrue at an interest rate of 15% per annum on any unpaid principal amount. The holder of the note can declare all or any portion of the unpaid balance, with all accrued interest, immediately due and payable. As of March 31, 2026, the outstanding principal balance of unsecured debt totaled $177,500.

F-14

Unsecured debt L: On November 14, 2024, the Company received an unsecured loan in the principal of $220,000 with a loan origination fee in the amount of $22,000, which will be amortized over the life of the loan as interest expense. The net proceeds from this loan were $220,000. The loan is unsecured and the initial payment of $8,667 was due on January 24, 2025. There were two months of no payments and then interest started accruing. Once the payments started there are a total of 34 monthly payments due on the 24th day of each following month, ending October 24, 2027. As of March 31, 2026, the outstanding principal balance of unsecured debt L totaled $136,475.

Unsecured debt N: On July 21, 2025, the Company received an unsecured loan in the principal of $325,000 with a loan origination fee in the amount of $32,500, which will be amortized over the life of the loan as interest expense. The net proceeds from this loan were $325,000. The loan is unsecured and is due for repayment on July 20, 2026. Interest will accrue at an interest rate of 12% per annum on any unpaid principal amount. If the Company defaults on the loan, the holder of the note can declare all or any portion of the unpaid balance with all accrued interest immediately due and payable. As of March 31, 2026, the outstanding principal balance of unsecured debt N totaled $346,667.

Unsecured debt O: On July 31, 2025, the Company received an unsecured loan in the principal of $75,000 with a loan origination fee in the amount of $7,500, which will be amortized over the life of the loan as interest expense. The net proceeds from this loan were $75,000. The loan is unsecured and is due for repayment on January 31, 2026. Interest will accrue at an interest rate of 12% per annum on any unpaid principal amount. If the Company defaults on the loan, the holder of the note can declare all or any portion of the unpaid balance with all accrued interest immediately due and payable. As of March 31, 2026, the outstanding principal balance of unsecured debt O totaled $82,500.

Unsecured debt P: On December 13, 2025, the Company received an unsecured loan in the principal of $75,000. The loan is unsecured and is due for repayment on December 12, 2026. Interest will accrue at an interest rate of 7.49% per annum on any unpaid principal amount. As of March 31, 2026, the outstanding principal balance of unsecured debt P totaled $74,336.

NOTE 5 – RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

In February 2022, the Company entered into a lease agreement for its warehouse facilities located at 7375 Commercial Way Suite 125, Henderson, Nevada 89011 with a term of 35 month 25 days that expired on January 31, 2025. Prior to February 4, 2022 the company was leasing a warehouse facility on a month-to-month lease. The average monthly base rent for the first 12 months is approximately $5,333. For the next 24 months of the lease, the average monthly base rent will be approximately $5,694. As part of the agreement the Company will be responsible to share any property operating expenses estimated as $1,017 per month. Pursuant to ASC 842, the estimated operating expenses was included with the base rent and was included in the calculations of the right of use assets. The Company recorded operating lease right-of-use of $175,765 and lease liabilities for operating lease of $175,765.

In February 2025, the Company entered into a lease agreement for its warehouse facilities located at 7375 Commercial Way Suite 125, Henderson, Nevada 89011 with a term of 36 month and will expire in 2028. The average monthly base rent for the first 12 months is approximately $6,677. For the next 12 months of the lease, the average monthly base rent will be approximately $6,677. For the next 12 months of the lease, the average monthly base rent will be approximately $6,889. As part of the agreement the Company will be responsible to share any property operating expenses estimated as $1,389 per month. Pursuant to ASC 842, the estimated operating expenses was included with the base rent and was included in the calculations of the right of use assets. The Company recorded operating lease right-of-use of $204,437 and lease liabilities for operating lease of $204,437.

On October 1, 2025, the Company assumed Gummy USA’s lease agreement for its warehouse facility located at 4560 Northgate Ct., Sarasota, FL 34234. The term of the original lease was 60 months and expires on September 30, 2028. The last three years of the lease monthly base rent averages $11,564. The Company assumed operating lease right-of-use of $391,945 and lease liabilities for operating lease of $391,945 as of October 1, 2025.

F-15

Supplemental statements of operations information related to leases are as follows:

		Month Ended
		March 31, 2026
Lease Cost
Cash paid for amounts included in the measurement of lease liabilities for the month ending March 2026		$-
Weighted average remaining lease term – operating leases (in years)		2.58 and 2.5
Average discount rate – operating leases		12.0% and 4.25%

		March 31, 2026
Operating leases
Right-of-use assets, net of amortization of $69,098		$135,339

Right-of-use assets, net of amortization of $58,210		333,735
Total of right-of-use assets		$469,074

Short-term operating lease liabilities		$(191,150)
Long-term operating lease liabilities		(280,403)
Total operating lease liabilities		$(471,553)

The following table summarizes the future undiscounted cash payments reconciled to the lease liability:

Year Ending		Operating Leases
2025 (remaining three months)		$-
2026		191,826
2027		222,843
2028		116,078
2029 and thereafter		-
Total lease payments		$530,747
Less: Imputed interest/present value discount		$(59,194)
Present value of lease liabilities		$471,553

NOTE 6 – NOTES PAYABLE

As of December 31, 2025, the Company had the following:

Note	Issuance Date	Maturity Date	Interest Rate	Original Principal Amount	Balance at March 31, 2026	Balance at December 31, 2025
Unsecured debt D	March 20, 2023	August 17, 2024	10%	330,000	-	-
Secured debt E	May 19, 2023	May 18, 2024	12.99%	131,000	-	-
Secured debt F	July 26, 2023	May 18, 2024	12.99%	196,000	-	-
Secured debt G	December 19, 2023	December 18, 2024	10%	94,600	-	-
Unsecured debt J	March 18, 2024	May 25, 2025	15%	247,300	-	-
Secured debt K	April 15, 2024	October 15, 2025	11%	36,630	-	-
Secured debt M	June 20, 2025	December 20, 2026	8.5%	173,600	18,824	67,184
Total notes payable				$1,609,130	$18,824	67,184
Debt discount and deferred financing costs				-	-	-
Total notes payable, net				$1,609,130	$18,824	67,184

F-16

Unsecured debt D: On March 20, 2023, the Company received an unsecured loan in the principal of $330,000 with a loan origination fee in the amount of $30,000, which was fully expensed as interest expense in this period. The net proceeds from this loan were $300,000. The loan is unsecured and the initial payment of $23,359 will be due on June 17, 2023. There will be fourteen monthly payments due on the 17th day of each following month, beginning on July 17, 2023 through August 17, 2024. Interest will accrue at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2023, the Company made a total in principal payments of $163,514 towards the unsecured debt D. During 2024, the Company made a total in principal payments of $46,718 towards the unsecured debt D. On March 18, 2024, the Company agreed with the borrower to close this unsecured debt D and roll over the outstanding principal in to unsecured debt J. As of March 31, 2026, the principal balance of the note was paid off.

Secured debt E: On May 19, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $131,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $11,700 and will be due June 19, 2023 with an additional eleven payments due each 19th of the month. During 2023, the Company has made principal payments totaling $10,282 towards the secured debt E. As of March 31, 2026, the principal balance of the note was paid off.

Secured debt F: On July 26, 2023, the Company agreed to a secured loan by any consigned inventory held at fulfillment centers and any rights, title or interest in their account. The principal loan amount was $196,000 and will have a loan term of twelve months with an annual interest rate of 12.99%, with a default rate of 14.99%. The first payment of principal and interest will be $17,505 and will be due August 26, 2023 with an additional eleven payments due each 26th of the month. During 2023, the Company has made principal payments totaling $85,601 towards the secured debt F. During 2024, the Company has made principal payments totaling $110,399 towards the secured debt F. As of March 31, 2026, the principal balance of the note was paid off.

Secured debt G: On December 19, 2023, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $86,000 and will have a loan term of twelve months. The note has a cost of funds equal to 10% of the loan amount or $8,600 and will be due upon acceptance of the loan amount. A total of $283 of the interest has been expensed in 2023. A total of $2,144 of the interest has been expensed in 2024. Payment will be made daily at a repayment rate of 14% of daily sales. and will be due December 21, 2023 and will continue until full amount owed is paid. During 2023, the Company has made principal payments totaling $2,074 towards the secured debt E. During 2024, the Company has made principal payments totaling $92,526 towards the secured debt E As of March 31, 2026, the principal balance of the note was paid off.

Unsecured debt J: On March 18, 2024, the Company received an unsecured loan in the principal of $247,300. The loan is unsecured and the initial payment of $19,365 will be due on April 25, 2024. There will be fourteen monthly payments due on the 25th day of each following month, beginning on April 25, 2024 through May 25, 2025. Interest will accrue at an interest rate of 15% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. The Company has accrued $4,992 in interest and will accrue an additional $8,111 of interest over the life of the loan. During 2024, the Company has made principal payments totaling $230,823 towards the unsecured debt J. As of March 31, 2026, the principal balance of the note was paid off.

Secured debt K: On April 15, 2024, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $33,000 and will have a loan term of eighteen months. The note has a cost of funds equal to 11% of the loan amount or $3,630 and will be due upon acceptance of the loan amount. A total of $1,109 of the interest has been expensed in 2024. Payment will be made daily at a repayment rate of 6% of daily sales and will be due October 15, 2024 and will continue until full amount owed is paid. During 2024, the Company has made principal payments totaling $36,630 towards the secured debt K. As of March 31, 2026, the principal balance of the note was paid off.

F-17

Secured debt M: On June 20, 2025, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $160,000 and will have a loan term of eighteen months. The note has a cost of funds equal to 8.5% of the loan amount or $173,600 and will be due upon acceptance of the loan amount. A total of $1,113 of the interest has been expensed in 2025. Payment will be made daily at a repayment rate of 24% of daily sales and will be due December 20, 2026 and will continue until full amount owed is paid. During 2025, the Company has made principal payments totaling $100,750 towards the secured debt M. During 2026, the Company has made principal payments totaling $51,760 towards the secured debt M. As of March 31, 2026 the principal balance of secured debt M was $18,824.

NOTE 7 – CONVERTIBLE DEBT

As of December 31, 2025, the Company had the following convertible debt outstanding:

Note	Issuance Date	Maturity Date	Interest Rate	Original Principal Amount	Balance at March 31, 2026	Balance at December 31, 2025
Convertible promissory note #1	July 28, 2016	January 19, 2017	8%	$15,000	$6,750	$6,750
Convertible promissory note #2	May 25, 2022	August 5, 2023	10%	154,000	-	-
Convertible promissory note #3	May 12, 2022	May 1, 2023	12%	200,000	-	-
Convertible promissory note #4	January 24, 2023	April 24, 2024	0%	388,888	-	111,330
Total notes payable				$757,888	$6,750	$118,080
Debt discount and deferred financing costs				-	-	-
Total notes payable, net				$757,888	$6,750	$118,080

Convertible promissory note #1:

On July 28, 2016, the Company executed the convertible promissory note #1 in the principal amount of $15,000, which is in default but management has not been able to make contact with this party, due to them living out of the country. The due date for this note was January 19, 2017 at an interest rate of 8%, with a default interest rate of 18%. The Company has calculated the derivative liability as if it is in default (but the note’s default interest rate stays the same at 8%) and will still accrue appropriate interest until the note is fully satisfied or converted into the Company’s common stock. The conversion option for this note coverts at a 54% discount to the market price based on the lowest trading prices in the last 20 days trading period. The outstanding balance on convertible promissory note #1 as of March 31, 2026 was $6,750.

The fair value of the derivative as of March 31, 2026 was determined to be $69,392 using the Black-Scholes option pricing model based on the following assumptions: common share price of $1.58 per share; expected exercise price of $0.88 per share; volatility of 199%; expected dividend yield of zero; and annual risk-free interest rate of 3.70%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $9,649. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

F-18

Convertible promissory note #2:

On May 25, 2022, the Company executed the convertible promissory note #2 in the principal amount of $154,000 with a loan origination fee in the amount of $15,400, which was fully expensed as interest expense in this period. The net proceeds from this note were $138,600. The loan is unsecured and the initial repayment of $14,488 was due on October 5, 2022. There will be ten additional monthly payments due on the 5th day of each following month, beginning on November 5, 2022 through August 5, 2023. Interest will accrual at an interest rate of 10% per annum on any unpaid principal amount. If the Company defaults on the loan, the default interest will increase to 16% per annum. During 2022, the Company has made principal payments totaling $43,465 towards the outstanding balance on convertible promissory note #2. During 2023, the Company has made additional principal payments towards convertible promissory note #2 totaling $110,535 which settled the entire principal balance in full. As of March 31, 2026, the principal balance of the note was paid off the principal balance of the note was paid off.

The fair value of the derivative was determined to be $0, due to being paid off, using the Black-Scholes option pricing model based, prior to the note being paid off, on the following assumptions: common share price of $2.5099 per share; expected exercise price of $6.00 per share; volatility of 235%; expected dividend yield of zero; and annual risk-free interest rate of 4.29%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $89,895. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #3:

On May 12, 2022, the Company executed the convertible promissory note #3 in the principal amount of $200,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on May 12, 2023. Interest shall accrue at the rate of 12% per annum. The outstanding balance on convertible promissory note #3 as of September 30, 2025 was paid in full. At any time on or after July 24, 2023, the holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The Company has been advised the holder of convertible promissory note #3 will be converting the full value of the outstanding principal and interest in the near future. The conversion price shall be $0.05 per share. On April 16, 2025, promissory note #3 was converted by the note holder and common stock shares were issued. As of March 31, 2026, the principal balance of the note was viewed as being fully paid.

The fair value of the derivative was determined to be $0, due to being paid off, using the Black-Scholes option pricing model based on the following assumptions: common share price of $1.94 per share; expected exercise price of $6.00 per share; volatility of 189%; expected dividend yield of zero; and annual risk-free interest rate of 4.31%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $184,011. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

Convertible promissory note #4:

On January 24, 2023, the Company executed the convertible promissory note #4 in the principal amount of $388,888 with a loan origination fee in the amount of $38,888, which was fully expensed as interest expense in this period, additionally there were $12,500 of legal costs and $31,500 of agent fees in which were also fully expenses in this period. The net proceeds from this loan were $306,000. The loan is unsecured and the principal and any unpaid accrued interest shall be due and payable on October 24, 2023 with an interest rate of 0%. Any unpaid balance at that time will start to accrue interest at a default rate of 20% per annum. On October 31, 2023 the note was extended to April 24, 2024 for an additional fee in the amount of $38,889. The additional fee will be amortized over the six month and in 2023 $12,962 was expensed. As of April 23, 2024, the Company signed a promissory note for the total outstanding balance. The note will bear interest at a rate of 10% and will have twenty-six payments in total. The payments will be $16,301.68 per month and

F-19

will increase on June 24, 2025 to a payment of $23,901.68. The total of principal paid during 2024 is $106,796 including debt discount. The total of principal paid during 2025 is $212,780 including debt discount. The total of principal paid during 2026 is $111,330 including debt discount. The convertible promissory note #4 was paid off during March 31, 2026 and has a balance owing of $0. The holder shall have the right, at his option, to convert the principal amount of the note, or any portion of such principal amount, plus accrued but unpaid interest into shares of the Company’s common stock. The conversion price means ninety percent (90%) of the lowest VWAP of the Company’s common stock for the five (5) consecutive Trading Days immediately preceding the date of the issuance of a Conversion Election.

The fair value of the derivative was determined to be $0 using the Black-Scholes option pricing model based on the following assumptions: common share price of $1.58 per share; expected exercise price of $0.88 per share; volatility of 199%; expected dividend yield of zero; and annual risk-free interest rate of 3.70%. The derivatives are classified as liabilities as they represent an obligation to deliver a variable number of shares of common stock in the future and are therefore required to be initially and subsequently measured at fair value each reporting period. The Company originally recorded a derivative liability in the amount of $174,234. The fair value of the derivative liability is remeasured each reporting period using the Black-Scholes option pricing model, and the change in fair value is recorded as an adjustment to the derivative liabilities account with the unrealized gains or losses reflect in other income – change in fair value on derivative.

NOTE 8 – DERIVATIVE LIABILITY

The Company evaluated the notes under the requirements of ASC 480 “Distinguishing Liabilities From Equity” (ASC 480) and concluded that the notes do not fall within the scope of ASC 480. The Company next evaluated the notes under the requirements of ASC 815 “Derivatives and Hedging Activities” and determined that the scope exception to ASC 815’s derivative accounting provisions does not apply. The Company then evaluated the embedded derivative criteria in ASC 815, and concluded that the conversion features meet all the embedded derivative criteria in ASC 815, and therefore, the conversion features meet the definition of an embedded derivative that should be separated from the notes and accounted for as a derivative liability.

The derivative liabilities were valued using a Black-Scholes option pricing model with the following average assumptions:

	March 31, 2026	Upon Issuance 2026	December 31, 2025	Upon Issuance 2025
Stock Price	$1.58	$0.00	$1.99	$0.00
Exercise Price	$0.88	$0.00	$0.694-1.719	$0.00
Expected Life	0	0	0	0.00
Volatility	199%	0%	175%	0%
Dividend Yield	0%	0%	0%	0%
Risk-Free Interest Rate	3.70%	0%	3.65%	0%
Convertible Notes	12,003	0	118,080	0.00
Total Fair Value	$69,392	$0.00	$352,411	$0.00

The expected life of the note was based on the remaining contractual term of the instruments. The Company uses the historical volatility of its Common Stock to estimate the future volatility for its Common Stock. The expected dividend yield was based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. The risk-free interest rate was based on rates established by the Federal Reserve Bank.

Consolidated Statement of Operations – Change in fair value on derivative

During the year ended December 31, 2025, the following transactions were recorded in the account “change in fair value on derivative”: (i) the change in the fair value of these derivative liabilities for the year ended December 31, 2025 resulted in a gain of $273,009.

During the month ended March 31, 2026, the following transactions were recorded in the account “change in fair value on derivative”: (i) the change in the fair value of these derivative liabilities for the month ended March 31, 2026 resulted in a gain of $283,019.

F-20

The details of derivative liability transactions for the month ended March 31, 2026 and year ended December 31, 2025 are as follows:

The change in Level 3 financial instrument fair value is as follows:

Balance, December 31, 2025	$625,420
Issued during the year ended December 31, 2025	-
Derivative liabilities debt premium	-
Change in fair value recognized in operations	(184,907)
Converted during the year ended December 31, 2025	(88,102)
Balance, December 31, 2025	$352,411
Issued during the month ended March 31, 2026	-
Derivative liabilities debt discount	-
Change in fair value recognized in operations	(283,019)
Converted during the month ended March 31, 2026	-
Balance, March 31, 2026	$69,392

NOTE 9 – INCOME TAXES

The effective income tax rate for the month ended March 31, 2026 and 2025 differs from the U.S. Federal statutory rate due to the following:

	March 2026	March 2025
Federal statutory income tax rate	$56,165	$111,681
Change in valuation allowance	(56,165)	(111,681)
	$-	$-

The components of the deferred tax assets and liabilities at March 31, 2026 and 2025 are as follows:

	March 2026	March 2025
Long-term deferred tax assets:
Federal net operating loss carryforwards	$56,165	$111,681
Valuation allowance	(56,165)	(111,681)
Net long-term deferred tax assets	$-	$-

NOTE 10 – STOCKHOLDERS’ EQUITY

Authorized Stock

The Company has authorized 75,000,000 common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought. During February 2017, the Company increased the authorized number of shares to 500,000,000. Also, the Company increased the authorized preferred stock to 75,000,000 shares and designated 25,000,000 shares of preferred stock to Series A Convertible Preferred Stock. During January 2018, the Company increased its authorized number of common shares to 1,000,000,000. During April 2018, the Company increased its authorized number of common shares to 2,500,000,000. The Board of Directors, in the future, has the authority to increase the authorized capital up to 4,000,000,000 shares based on shareholder approval. On December 29, 2023 the Company decreased its authorized number of common shares to 50,000,000.

The Company effectuated a reverse stock split of 120-for-1 as of December 29, 2023. Due to the reverse stock split the Company added 9,802 common stock shares from the fractional shares issued by the DTC.

F-21

On October 16, 2017, the Company filed an Amended and Restated Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of the Series A Convertible Preferred Stock (the “Amended Certificate”) with the Secretary of State of the State of Nevada. The Amended Certificate reduces the number of preferred shares designated as Series A Preferred Stock from 25,000,000 shares to 1,333,334 shares. The Amended Certificate also changes the conversion and voting rights of the Series A Preferred Stock. The Series A Preferred Stock is now convertible into the number of shares of Company common stock equal to 0.00006% of its outstanding common stock upon conversion. The voting rights of the Series A Preferred Stock are now equal to the number of shares of common stock into which the Series A Preferred Stock may convert.

As of March 31, 2026, there are no outstanding shares of preferred stock. All the preferred stock was converted in common stock on February 4, 2019.

Common Share Issuances

During the month ended March 31, 2026, the Company issued 20,000 shares of common stock for services. They were issued at$1.94 per share.

There were no shares issued during the first quarter 2025. During the three months ended June 30, 2025, the Company issued 4,584 shares of common stock for services. They were issued at $2.00 per share. Additionally, the Company issued 147,500 shares of common stock for the conversion of the note payable. They were issued at $2.00 per share. During the three months ended September 30, 2025, the Company issued 653,458 shares of common stock for services. They were issued at $1.80 per share, but 520,958 elected to use the current 409a valuation. On July 19, 2025, the Company issued 13,075,920 shares of common stock due to the merger with Gummy USA, LLC. These shares were rescinded on September 26, 2025. The shares of common stock were reissued as of October 1, 2025. During the three months ended December 31, 2025, there were no shares issued.

Warrant Issuances

During the three months ending March 31, 2023, the Company issued 61,846 warrants to 2 unrelated parties at a per share price of $5.6592. On February 2, 2022, the Company issued 16,667 warrants to an individual at a per share price of $6.00. As of December 31, 2023, there were 195,180 warrants outstanding, of which 195,180 warrants are fully vested. As of June 30, 2024, there were 132,680 warrants outstanding, of which 132,680 warrants are fully vested.

			Weighted-
		Weighted-	Average
		Average	Remaining	Aggregate
		Exercise	Contractual	Intrinsic
	Warrants	Price	Life (Years)	Value

Outstanding at December 31, 2025	116,013	$7.22	1.34	$-
Granted	-	-	-	-
Forfeited	-	-	-	-
Exercised	-	-	-	-
Outstanding at March 31, 2026	116,013	$7.22	1.09	$-

Vested and expected to vest at March 31, 2026	116,013	$7.22		$-

Exercisable at March 31, 2026	116,013	$7.22		$-

At March 31, 2026, the intrinsic value of these stock warrants was $0 as the exercise price of these stock warrants were greater than the market price.

F-22

Share Conversion Agreements

All of the holders of the Company’s Series A Convertible Preferred Stock (the “Preferred Holders”) entered into a Preferred Stock Conversion Agreement. Pursuant to the Conversion Agreements, the Preferred Holders converted their shares of preferred stock into common stock, effective as of the Exchange. As a result, no shares of the Company’s Series A Convertible Preferred Stock are outstanding. An aggregate of 15,592,986 shares of common stock were issued to the Preferred Holders. The Preferred Holders agreed to convert each share of Series A Convertible Preferred Stock into eighteen (18) shares of common stock and agreed to retire a total of 467,057 shares of Series A Convertible Preferred Stock. The Company cancelled the retired shares.

Omnibus Stock Grant and Option Plan

The following summary of options activity for the month ended March 31, 2026 is presented below:

			Weighted-
		Weighted-	Average
		Average	Remaining	Aggregate
		Exercise	Contractual	Intrinsic
	Options	Price	Life (Years)	Value

Outstanding at December 31, 2025	15,333	$6.00	1.16	-
Granted	-	-	-	-
Forfeited	-	-	-	-
Exercised	-	-	-	-
Outstanding at March 31, 2026	15,833	$6.00	0.91	$-

Vested and expected to vest at March 31, 2026	15,833	$6.00		$-
Exercisable at March 31, 2026	15,833	$6.00		$-

At December 31, 2025, the intrinsic value of these stock options was $0 as the exercise price of these stock options were greater than the market price.

The following summary of restricted stock units’ activity for the month ended March 31, 2026 is presented below:

			Weighted-
			Weighted-
			Average
			Grant Date
	Shares		Fair Value

Non-vested at December 31, 2025		-		-
Granted		-		-
Vested		-		-
Forfeited		-		-
Non-vested at March 31, 2026		-		-

As of December 31, 2023, the amount of unvested compensation related to issuances of restricted stock units’ fair value was $423,910. This amount will be amortized and expensed over the life of the contract and will be included in selling, general and administrative expenses in the accompanying consolidation statements of operations.

As of December 31, 2024, the amount of unvested compensation related to issuances of restricted stock units’ fair value was $77,230. This amount will be amortized and expensed over the life of the contract and will be included in selling, general and administrative expenses in the accompanying consolidation statements of operations. As of March 31, 2026, the intrinsic value of these restricted stock unit was $0 as the Company decided to let these restricted stock units expire.

F-23

The fair value of share options, units, and warrants are estimated using the Black-Scholes option pricing method based on the following weighted-average assumptions:

	Month Ending
	March 31, 2026			December 31, 2025
Risk-free interest rate		3.70	%		4.13	%
Average expected term (years)		1.09 years			1.09 years
Expected volatility		199	%		171	%
Expected dividend yield		-			-

NOTE 11 – BUSINESS SEGMENT INFORMATION

As of March 31, 2026, the Company operated in three reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the month ended March 31, 2026.

	CONSOLIDATED	HEALTH SUPPLEMENTS			CORPORATE
		BergaMet	Gummy USA	UBN
Revenue	1,610,744	869,892	740,852	-	-
Cost of Revenue	622,043	406,472	214,697	-	-
Long-lived Assets	526,647	19,154	4,766	502,727	-
Gain (Loss) Before Income Tax	(200,590)	(54,922)	(232,440)	(498)	87,270
Identifiable Assets	520,752	453,377	67,375	-	-
Depreciation and Amortization	156,168	893	155,275	-	-

As of December 31, 2025, the Company operated in two reportable segments (Corporate and Health Supplements) supported by a corporate group which conducts activities that are non-segment specific. The following table presents selected financial information about the Company’s reportable segments for the nine months ended December 31, 2025.

	CONSOLIDATED	HEALTH SUPPLEMENTS			CORPORATE
		BergaMet	Gummy USA	UBN
Revenue	4,511,997	3,751,247	760,750	-	-
Cost of Revenue	2,433,103	2,219,096	214,007	-	-
Long-lived Assets	1,140,342	186,978	450,637	502,727	-
Gain (Loss) Before Income Tax	(881,119)	53,408	(154,242)	(300)	(779,985)
Identifiable Assets	843,357	737,862	105,495	-	-
Depreciation and Amortization	152,192	1,963	150,229	-	-

Currently, BergaMet and UBN’s customers are located in the United States of American and Canada. Their revenues to the Company’s customers are not material to its overall total sales. The Company’s largest customers, Natural Grocers and Emerson Ecologics, LLC, account for less than 1% of its total sales in the month ended March 31, 2026 and year ended December 31, 2025.

NOTE 12 – SUBSEQUENT EVENTS

The Company evaluated its March 31, 2026 financial statements for subsequent events through May 14, 2026, the date the financial statements were available to be issued.

On April 30, 2026, the Company agreed to a secured loan by any rights, title or interest in their account. The principal loan amount was $140,000 and will have a loan term of eighteen months. The note has a cost of funds equal to 9.2% of the loan amount or $152,880 and will be due upon acceptance of the loan amount.

On May 5, 2026, secured debt M was paid off in full.

F-24

ITEM 2Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; raw material costs and availability; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

Although the forward-looking statements in this Quarterly Statement reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

The following discussion and analysis of financial condition and results of operations of the Company is based upon, and should be read in conjunction with, its unaudited financial statements and related notes elsewhere in this Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States.

Overview

Since our acquisitions of Bergamet and UBN, we have focused on increasing revenue, maintaining our margins, and generating positive cash flow from our existing operations. In part, at least with respect to Bergamet and UBN, we have been successful in meeting these objectives and our business has remained relatively unchanged. In October 2025, we acquired GummyUSA, which accelerated our revenue growth and increased our gross profit.

We are a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. Our proprietary and patented products target select high-growth categories within the multibillion-dollar nutraceuticals market, such as heart, brain and immune health. Our products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy. Our mission is to acquire or create products with health and performance benefits that have mass consumer appeal. GummyUSA added contract manufacturing and formulation services to our offering, and we now operate at the intersection of nutraceutical manufacturing, drug delivery innovation, and precision formulation technologies.

Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our historical operating subsidiaries, BergaMet NA, LLC, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Our GummyUSA acquisition (in 2025), which is operated as our subsidiary HE Gummy USA, Inc., added technical capabilities and a manufacturing architecture to support our own needs as well as those of third-parties.

Our Financial Condition and Going Concern Issues

Our net loss from inception to December 31, 2025 was $20,121,462, and we had limited cash resources at December 31, 2025 of $146,935. Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our auditor’s report reflects that our ability to continue as a going concern is dependent upon our ability to raise additional capital from the sale of common stock or other means and, ultimately, the achievement of significant operating revenues. If we are unable to continue as a going concern, our business will fail and stockholders will lose their investment in our company. No assurance can be given that such financing will be available or, if available, that it will be on commercially favorable terms. Moreover, financing will likely be dilutive to our stockholders.

Results of Operations for the Three Months Ended March 31, 2026 and 2025

Introduction

We had revenues of $1,610,744 for the three months ended March 31, 2026, compared to $931,280 for the three months ended March 31, 2025. Our cost of revenue for the three months ended March 31, 2026 was $622,043, compared to $506,295 for the three months ended March 31, 2025.

Our operating expenses were $1,317,403 for the three months ended March 31, 2026, compared to $533,833 for the three months ended March 31, 2025. Our operating expenses consisted entirely of general and administrative expenses.

Our net income (loss) was $(200,590) for the three months ended March 31, 2026, compared to $(398,860) for the three months ended March 31, 2025.

Revenues and Net Operating Loss

Our revenue, cost of revenue, gross profit, operating expenses, other income (expense), and net loss for the three months ended March 31, 2026 and 2025 were as follows:

		Three Months Ended		Three Months Ended
		March 31, 2026		March 31, 2025

Revenue	$	1,610,744	$	931,280

Cost of Revenue		622,043		506,295

Gross Profit		988,701		424,985

Operating expenses:
General and administrative		1,317,403		533,833
Total operating expenses		1,317,403		533,833

Other income (expense)
Interest expenses, net of interest income		(84,907)		(34,558)
Change in fair value on derivative		283,019		(255,454)
Gain/loss of disposal of assets		70,000		-
Total other income (expense)		128,112		(290,011)

Net income (loss)	$	(200,590)	$	(398,860)

Revenues

We had revenues of $1,610,744 for the three months ended March 31, 2026, compared to $931,280 for the three months ended March 31, 2025, an increase of $679,464, or 73%. We expect revenue growth to increase as our direct consumer sales and marketing efforts continue to perform.

Cost of Revenue

Our cost of revenue for the three months ended March 31, 2026 was $622,043, compared to $506,295 for the three months ended March 31, 2025, an increase of $115,748, or 23%. Gross profit for the three months ended March 31, 2026 was $988,701, compared to $424,985 for the three months ended March 31, 2025, an increase of $563,716, or 61%.

Cost of revenue as a percentage of revenues was 39% for the three months ended March 31, 2026, compared to 54% for the three months ended March 31, 2025.

General and Administrative

Our general and administrative expenses were $1,317,403 for the three months ended March 31, 2026, compared to $533,833 for the three months ended March 31, 2025, an increase of $783,570, or 147%. In the three months ended March 31, 2026, general and administrative expenses consisted mainly of advertising of $223,586, consulting fees of $223,643, stock-based compensation $113,801, salaries and wages of $240,906 and selling fees of $109,471. In the three months ended March 31, 2025, general and administrative expenses consisted mainly of advertising of $222,827, consulting fees of $105,500, stock-based compensation $48,991, salaries and wages of $48,535 and accounting and legal fees of $36,650. For the three months ended March 31, 2026, the increase was due in part to additional salaries and wages and stock-based compensation expense recognition.

Other Income (Expense)

Other income (expense) was $128,112 for the three months ended March 31, 2026, compared to $(290,011) for the three months ended March 31, 2025, an increase of $418,123, or 144%. In the three months ended March 31, 2026, other income (expense) consisted of interest expense, net of interest income of $(84,907), change in fair value on derivative of $283,019, and gain/loss of disposal of assets of $(70,000). In the three months ended March 31, 2025, other income (expense) consisted of interest expense, net of interest income of $(34,558) and change in fair value on derivative of $(255,454). Change in fair value of derivative was related to reduction in convertible debts balances and the conversion of convertible debts into shares of common stock.

Net Income (Loss)

Net income (loss) was $(200,590), or $(0.01) per share, for the three months ended March 31, 2026, compared to $(398,860), or $(0.13) per share, for the three months ended March 31, 2025.

Our net income (loss) varies from period to period primarily because of the change in fair value on derivative and our increase in general and administrative expenses.

Liquidity and Capital Resources

Introduction

During the three months ended March 31, 2026, we had positive operating cash flows. Our cash on hand as of March 31, 2026 was $164,385. While we had positive net cash from operations for the three months ended March 31, 2026 and 2025, we have both short and medium-term cash needs. We anticipate that these needs will be satisfied through increased revenues and the issuance of debt or the sale of our securities until such time as our cash flows from operations will consistently satisfy our cash flow needs.

Our cash, current assets, total assets, and current and total liabilities as of March 31, 2026 and December 31, 2025 were as follows:

	March 31,		December 31,		Increase/
	2026		2025		(Decrease)

Cash	$	164,385	$	146,935	$	17,450
Total Current Assets	1,088,079			1,327,317	(239,238)
Total Assets	27,318,838			27,824,664	(505,826)
Total Current and Total Liabilities	3,337,239			3,795,099	(457,860)

Our total current assets decreased slightly during the three months ended March 31, 2026 primarily as a result of our decrease in inventory of $322,605, offset by an increase in accounts liabilities of $157,398 and cash of $17,450. Our total assets decreased slightly as a result of our decrease in fixed assets of $201,022, interest expense of $84,909, and accrued interest payable of $75,210. Our accumulated deficit increased during the three months ended March 31, 2026, by $200,590 to $20,322,053.

In order to repay our obligations in full or in part when due, we will be required to raise significant capital from other sources. There is no assurance, however, that we will be successful in these efforts.

Cash Requirements

Our cash on hand as of March 31, 2026 was $164,385. While we had positive net cash from operations for the three months ended March 31, 2026 and 2025, we have both short and medium-term cash needs and we will need to continue to fund operations by raising capital from the sale of our stock and debt financings.

Sources and Uses of Cash

Operating Activities

We had net cash from operating activities of $105,970 for the three months ended March 31, 2026, compared to $60,021 for the three months ended March 31, 2025. We use our cash for normal business operations. Our net cash from operating activities for the three months ended March 31, 2026 consisted of our net loss of $200,590, plus in part a change in fair value on derivative liability of $283,019 and accrued liabilities of $157,396, offset in part by our inventory of $322,605, depreciation and amortization of $156,168, and warrants issued for services of $113,801. Our net cash from operating activities for the three months ended March 31, 2025 consisted of our net loss of $398,860, plus in part lease liability-long term of $60,194 and changes in accounts receivable of $58,977, offset in part by our change in fair value on derivative liability of $255,454 and our decrease in inventory of $218,589.

Investing Activities

Our net cash used in investing activities was $zero for the three months ended March 31, 2026 and the three months ended March 31, 2025.

Financing Activities

Our net cash provided by financing activities for the three months ended March 31, 2026 was $(88,520), compared to $(53,243) for the three months ended March 31, 2025. Our net cash provided by financing activities for the three months ended March 31, 2026 consisted primarily of proceeds from the issuance of notes payable of $176,000, offset in part by payments for repayment of notes payable of $110,492 and payments for repayment of convertible debt of $106,000.

ITEM 3Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4Controls and Procedures

(a)Disclosure Controls and Procedures

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of March 31, 2026, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2026, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in our Annual Report on Internal Control Over Financial Reporting filed in our Annual Report on Form 10-K.

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all errors and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive officers have determined that our disclosure controls and procedures are effective at doing so, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

(b)Changes in Internal Control over Financial Reporting

No change in our system of internal control over financial reporting occurred during the period covered by this report, the three-month period ended March 31, 2026, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1Legal Proceedings

There are no updates to the disclosure of legal proceedings in our Annual Report on Form 10-K.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

ITEM 1ARisk Factors

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2Unregistered Sales of Equity Securities and Use of Proceeds

On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.

There have been no other events which are required to be reported under this Item.

ITEM 3Defaults Upon Senior Securities

There have been no events which are required to be reported under this Item.

ITEM 4Mine Safety Disclosures

Not applicable.

ITEM 5Other Information

None.

ITEM 6Exhibits

(a)Exhibits

Exhibit No.		Description

3.1 (1)		Articles of Incorporation of Grey Cloak Tech Inc. filed December 19, 2014

3.2 (1)		Certificate of Amendment of Articles of Incorporation filed October 23, 2020

3.3 (2)		Certificate of Amendment of Articles of Incorporation filed December 19, 2023

3.3 (3)		Bylaws of Grey Cloak Tech Inc.

31.1		Certification of our Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of our Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of our Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of our Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Schema Document

101.CAL		XBRL Calculation Linkbase Document

101.DEF		XBRL Definition Linkbase Document

101.LAB		XBRL Labels Linkbase Document

101.PRE		XBRL Presentation Linkbase Document

(1)	Incorporated by reference from our Registration Statement on Form S-1/A filed with the Commission on August 28, 2023.

(2)	Incorporated by reference from our Current Report on Form 8-K filed with the Commission on December 29, 2023.

(3)	Incorporated by reference from our Registration Statement on Form S-1 filed with the Commission on March 6, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Healthy Extracts Inc.


Dated: May 14, 2026	/s/Kevin “Duke” Pitts
	By:Kevin “Duke” Pitts
	Its:President

HEALTHY EXTRACTS INC. 10-Q